Corrigendum to: “IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity” (OncoImmunology, (2015) 4, 9, DOI 10.1080/2162402X.2014.1002721);IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity

OncoImmunology

Volumn 4, Issue 9, 2015, Pages 1-13

  Bahri, Rajia ^a,b   Pateras, Ioannis S ^c   Dorlando, Orietta ^b   Goyeneche Patino, Diego A ^b   Campbell, Michelle ^a   Polansky, Julia K ^b   Sandig, Hilary ^a   Papaioannou, Marilena ^c   Evangelou, Kostas ^c   Foukas, Periklis G ^c   Gorgoulis, Vassilis G ^a,c,d   Bulfone Paus, Silvia ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

AOM; Colitis associated cancer; Cytokines; DSS; IL 15; Immunity; Tumor

Indexed keywords

AZOXYMETHANE; INTERLEUKIN 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COLITIS; COLON CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM; TUMOR IMMUNITY; UPREGULATION;

EID: 84944447448     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1193395     Document Type: Erratum

References (64)

1. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22:99-108; PMID:21531164; http://dx.doi.org/10.1016/j.cytogfr. 2011.04.001
2. van Heel DA. Interleukin 15: its role in intestinal inflammation. Gut 2006; 55:444-5; PMID:16531523; http://dx.doi.org/10.1136/gut.2005.079335
3. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996; 156:735-41
4. Schulthess J, Meresse B, Ramiro-Puig E, Montcuquet N, Darche S, Begue B, Ruemmele F, Combadi-Egravere C, Di Santo JP, Buzoni-Gatel D et al. Interleukin-15-dependent NKp46C innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity 2012; 37:108-21; PMID:22705105; http://dx.doi.org/10.1016/j.immuni. 2012.05.013
5. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13:2822-30; PMID:8026467
6. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965-8; PMID:8178155; http://dx.doi. org/10.1126/science.8178155
7. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 1994; 91:4940-4; PMID:8197161; http://dx.doi. org/10.1073/pnas.91.11.4940
8. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537-47; PMID:12433361; http://dx.doi.org/10.1016/S1074-7613(02)00429-6
9. Castillo EF, Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine 2012; 59:479-90; PMID:22795955; http://dx.doi.org/ 10.1016/j.cyto.2012.06.017
10. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-80; PMID:10704459; http://dx.doi.org/10.1084/jem.191.5.771
11. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-76; PMID:9846488; http://dx.doi.org/10.1016/S1074-7613(00)80664-0
12. Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, Yang Y, Savan R, Subleski JJ, Yin XM et al. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 2009; 69:3986-94; PMID:19366803; http://dx.doi.org/ 10.1158/0008-5472.CAN-08-3735
13. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T, Frank B, Lee NH, Loughran TP Jr. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008; 112:770-81; PMID:18477771; http://dx.doi.org/10.1182/blood-2007-11-121871
14. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, Kitadai Y, Fidler IJ. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 2003; 9:4802-10; PMID:14581351
15. Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, Facco M, Adami F, Rodeghiero F, Agostini C, Semenzato G. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996; 87:3327-35; PMID:8605349
16. Kuniyasu H, Oue N, Nakae D, Tsutsumi M, Denda A, Tsujiuchi T, Yokozaki H, Yasui W. Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology 2001; 69:86-95; PMID:11752902; http://dx.doi.org/10.1159/ 000048761
17. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 2012; 22:645-55; PMID:23153537; http://dx.doi.org/10.1016/j.ccr.2012.09.009
18. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2012; 35:229-44; PMID:23161445; http://dx.doi.org/ 10.1007/s00281-012-0352-6
19. Wang K, Grivennikov SI, Karin M. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis 2013; 72 Suppl 2: ii100-3; PMID:23253923; http://dx.doi.org/10.1136/ annrheumdis-2012-202201
20. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118:2516-25; PMID:18521188; http://dx.doi.org/10.1172/jci35073
21. Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E, Cui L, McFaline JL, Mobley M, Ge Z et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci U S A 2012; 109:E1820-9; PMID:22689960; http://dx.doi.org/10.1073/pnas.1207829109
22. Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Inter J Cancer 2013; 132:905-15; PMID:22674296; http://dx.doi.org/10.1002/ijc.27660
23. Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bisonni R, Floriani I et al. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009; 9:78-84; PMID:19104506; http://dx.doi.org/10.1038/tpj. 2008.16
24. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenetics Genomics 2009; 19:95-102; PMID:18987561; http:// dx.doi.org/10.1097/FPC.0b013e32831a9ad1
25. Nieminen U, Jussila A, Nordling S, Mustonen H, Farkkila MA. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer 2014; 134:189-96; PMID:23797639; http://dx.doi.org/10.1002/ijc.28346
26. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13:759-71; PMID:24154716; http://dx. doi.org/10.1038/nrc3611
27. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996; 39:87-92; PMID: 8881816; http://dx.doi.org/10.1136/gut.39.1.87
28. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007; 2:1998-2004; PMID:17703211; http://dx.doi.org/10.1038/nprot.2007.279
29. Obermeier F, Hausmann M, Kellermeier S, Kiessling S, Strauch UG, Duitman E, Bulfone-Paus S, Herfarth H, Bock J, Dunger N et al. IL-15 protects intestinal epithelial cells. Eur J Immunol 2006; 36:2691-9; PMID:16981178; http://dx.doi.org/10.1002/eji. 200535173
30. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j.tips. 2011.09.004
31. Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res 2013; 73:139-49; PMID:23149919; http://dx.doi.org/10.1158/ 0008-5472.CAN-12-2660
32. Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A 2009; 106:7513-8; PMID:19383782; http://dx. doi.org/10.1073/pnas.0902637106
33. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000; 97:11445-50; PMID:11016962; http://dx.doi. org/10.1073/pnas.200363097
34. Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 1996; 111:1706-13; PMID:8942753; http://dx.doi.org/ 10.1016/S0016-5085(96)70036-7
35. Nishimura H, Fujimoto A, Tamura N, Yajima T, Wajjwalku W, Yoshikai Y. A novel autoregulatory mechanism for transcriptional activation of the IL-15 gene by a nonsecretable isoform of IL-15 generated by alternative splicing. FASEB J 2005; 19:19-28; PMID:15629891; http://dx.doi.org/10.1096/fj.04-2633com
36. Chen J, Huang XF. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009; 8:1313-7; PMID:19502780; http://dx.doi.org/10.4161/cbt.8. 14.8983
37. Gomez-Nicola D, Spagnolo A, Guaza C, Nieto-Sampedro M. Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice. Exp Neurol 2010; 222:235-42; PMID:20070942; http://dx.doi.org/ 10.1016/j.expneurol.2009.12.034
38. Rauch DA, Harding JC, Ratner L. IL-15 deficient tax mice reveal a role for IL-1alpha in tumor immunity. PloS One 2014; 9:e85028; PMID:24416335; http:// dx.doi.org/10.1371/journal.pone.0085028
39. Yoshihara K, Yajima T, Kubo C, Yoshikai Y. Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut 2006; 55:334-41; PMID:16162679; http://dx. doi.org/10.1136/gut.2005.076000
40. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16:6019-28; PMID:20924130; http://dx.doi.org/ 10.1158/1078-0432.CCR-10-1966
41. Nishiyama R, Sakaguchi T, Kinugasa T, Gu X, MacDermott RP, Podolsky DK, Reinecker HC. Interleukin-2 receptor beta subunit-dependent and-independent regulation of intestinal epithelial tight junctions. J Biol Chem 2001; 276:35571-80; PMID:11466322; http://dx.doi.org/10.1074/jbc. M106013200
42. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68:2972-83; PMID:18413767; http://dx.doi.org/10.1158/0008-5472.CAN-08-0045
43. Davies E, Reid S, Medina MF, Lichty B, Ashkar AA. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. J Leukocyte Biol 2010; 88:529-36; PMID:20538758; http://dx.doi.org/10.1189/ jlb.0909648
44. Gillgrass A, GillN, Babian A, Ashkar AA.The absence or overexpression of IL-15 drastically alters breast cancer metastasis via effects on NK cells, CD4 T cells, and macrophages. J Immunol 2014; 193:6184-91; PMID:253559 26; http://dx.doi.org/10.4049/jimmunol.1303175
45. Buonocore S, Ahern PP, Uhlig HH, Ivanov, II, Littman DR, Maloy KJ, Powrie F. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464:1371-5; PMID:20393462; http://dx. doi.org/10.1038/nature08949
46. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7; PMID:12411307; http://dx. doi.org/10.1182/blood-2002-05-1461
47. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118:534-44; PMID:18172556; http://dx.doi.org/ 10.1172/jci33194
48. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129:969-84; PMID:16143135; http://dx.doi. org/10.1053/j.gastro.2005.06.071
49. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, Harrison O, Powrie F. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210:917-31; PMID:23589566; http://dx.doi.org/ 10.1084/jem.20122308
50. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pag-Egraves F et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http:// dx.doi.org/10.1158/0008-5472.CAN-10-2907
51. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15:1016-22; PMID:19701202; http://dx.doi.org/10.1038/ nm.2015
52. Perera LP, Goldman CK, Waldmann TA. IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J Immunol 1999; 162:2606-12; PMID:10072502
53. Chen JP, Liao NS, Lai SL, Hsu L, Mao WY, Ku MC, Liao F. Reduced 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity response in IL-15 receptor alpha-deficient mice correlates with diminished CCL5/ RANTES and CXCL10/IP-10 expression. Eur J Immunol 2005; 35:690-8; PMID:15719370; http:// dx.doi.org/10.1002/eji.200425577
54. Chenoweth MJ, Mian MF, Barra NG, Alain T, SonenbergN, Bramson J, Lichty BD, RichardsCD,Ma A, Ashkar AA. IL-15 can signal via IL-15Ralpha, JNK, and NFkappaB to drive RANTES production by myeloid cells. J Immunol 2012; 188:4149-57; PMID:22447977; http:// dx.doi.org/10.4049/jimmunol.1101883
55. Lavergne E, Combadiere C, Iga M, Boissonnas A, Bonduelle O, Maho M, Debr-Eacute P, Combadiere B. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Iimmunol 2004; 173:3755-62; PMID:15356122; http://dx.doi.org/10.4049/jimmunol.173.6.3755
56. Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 2009; 69:6331-8; PMID:19602595; http://dx.doi.org/10.1158/0008-5472.CAN-08-4329
57. DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011; 471:220-4; PMID:21307853; http://dx.doi.org/10.1038/nature 09849
58. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT. Chemokines in human colorectal carcinoma. Anticancer Res 2005; 25:3581-4; PMID:16101183
59. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140:1807-16; PMID:21530747; http://dx.doi.org/10.1053/j.gastro. 2011.01.057
60. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; PMID:15829965; http://dx.doi.org/10.1038/nature 03485
61. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23:634-46; PMID:23680148; http://dx.doi.org/ 10.1016/j.ccr.2013.03.022
62. Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, Neely GG, Zwick RH, Sigl V, Forni G et al. The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet 2011; 43:212-9; PMID:21317887; http://dx. doi.org/10.1038/ng.767
63. Kotsinas A, Evangelou K, Zacharatos P, Kittas C, Gorgoulis VG. Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. Am J Pathol 2002; 161:1619-34; PMID:12414510; http://dx.doi.org/10.1016/S0002-9440(10)64440-9
64. Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, Nebreda AR. Dual function of p38alpha MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. Cancer Cell 2014; 25:484-500; PMID:24684847; http://dx.doi.org/10.1016/j.ccr. 2014.02.019